CAR20(NAP)-T Therapy for B Cell Lymphoma (CARMA-01 Study)
Status:
RECRUITING
Trial end date:
2027-12-30
Target enrollment:
Participant gender:
Summary
The purpose is to study the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of CAR20(NAP)-T for patients with B-cell malignancies.
Phase:
PHASE1
Details
Lead Sponsor:
Uppsala University
Collaborators:
Elicera Therapeutics Karolinska University Hospital Uppsala University Hospital